| Literature DB >> 24037208 |
Patricia Vollú Silva1, Raquel Souza Cruz, Luiz Sérgio Keim, Geraldo Renato de Paula, Bernadete Teixeira Ferreira Carvalho, Leonardo Rocchetto Coelho, Maria Cícera da Silva Carvalho, Joel Mauricio Corrêa da Rosa, Agnes Marie Sá Figueiredo, Lenise Arneiro Teixeira.
Abstract
We analysed the antimicrobial susceptibility, biofilm formation and genotypic profiles of 27 isolates of Staphylococcus haemolyticus obtained from the blood of 19 patients admitted to a hospital in Rio de Janeiro, Brazil. Our analysis revealed a clinical significance of 36.8% and a multi-resistance rate of 92.6% among these isolates. All but one isolate carried the mecA gene. The staphylococcal cassette chromosome mec type I was the most prevalent mec element detected (67%). Nevertheless, the isolates showed clonal diversity based on pulsed-field gel electrophoresis analysis. The ability to form biofilms was detected in 66% of the isolates studied. Surprisingly, no icaAD genes were found among the biofilm-producing isolates.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24037208 PMCID: PMC3970699 DOI: 10.1590/0074-0276108062013022
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Antimicrobial resistance, pulsed-field gel electrophoresis (PFGE) patterns, staphylococcal cassette chromosome mec (SCC mec ) types and biofilm formation of 27 Staphylococcus haemolyticus isolated from blood
| Isolate | Collection | Hospital unit | Antimicrobial resistance | PFGE | SCC
| Biofilm |
|---|---|---|---|---|---|---|
| 05/08 (P1, M, 41) | 6 Jan 2008 | Intensive care | PEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT, TEI | K | VII | NP |
| 33/08(P2, F, 37) | 4 Nov 2007 | Internal medicine | PEN, OXA, CEF, CLI, ERY, TET, GEN, CIP, SXT | K | VII | 0.56 ± 0.17 |
| 37/08 (P2) | 4 Nov 2007 | Neurosurgery | PEN, OXA, CEF, CLI, TET, GEN, CIP, SXT | I | VII | 0.27 ± 0.12 |
| 27/08 (P3, M, 24) | 31 Oct 2007 | Neurosurgery | PEN, OXA, CEF, CLI, ERY, RIF, GEN, CIP, SXT | H 2 | I | NP |
| 47/08 (P3) | 31 Oct 3007 | Neurosurgery | PEN, OXA, CEF, CLI, ERY, RIF, GEN, CIP, SXT | H 1 | I | 1.32 ± 0.54 |
| 32/08 (P4, F, 82) | 29 Oct 2007 | Internal medicine | PEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXT | L | VIII | 0.57± 0.09 |
| 43/08 (P4) | 29 Oct 2007 | Internal medicine | PEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT | ND | I | 0.89 ± 0.17 |
| 34/08 (P5, F, 34) | 25 Oct 2007 | Internal medicine | PEN, OXA, CEF, CLI, ERY, CHL, CIP | J | VIII | NP |
| 56/08 (P6, F, 93) | 25 Oct 2007 | Internal medicine | PEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT | G | VII | NP |
| 65/08 (P7, F, 25) | 4 Feb 2008 | Intensive care | PEN, OXA, CEF, CLI, ERY, CHL, TET, GEN, CIP, SXT | A | I | 1.45 ± 0.38 |
| 69/08 (P7) | 4 Feb 2008 | Intensive care | PEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXT | F | I | 0.25 ± 0.10 |
| 74/08 (P8, M, 57) | 28 Jan 2008 | Neurosurgery | PEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXT | A | I | 3.38 ± 0.94 |
| 136/08 (P8) | 28 Jan 2008 | Neurosurgery | PEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXT | B | I | 1.60 ± 0.66 |
| 85/08 (P9, M, NR) | 4 Jan 2008 | Intensive care | PEN, OXA, CEF, CHL | O | VII | NP |
| 86/08 (P9) | 4 Jan 2008 | Intensive care | PEN, OXA, CEF, CLI, ERY, CHL, TET, GEN, CIP, SXT | A | I | 2.60 ± 0.46 |
| 140/08 (P10, F, NR) | 25 Feb 2008 | Internal medicine | PEN, OXA, CEF, CLI, ERY, CHL, TET, RIF, GEN, CIP, SXT | G | VII | NP |
| 142/08 (P11, M, NR) | 28 Feb 2008 | Coronary | PEN, OXA, CEF, CLI, ERY, TET, GEN, CIP, SXT | C 1 | I | NP |
| 153/08 (P11) | 28 Feb 2008 | Coronary | PEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT | C 2 | I | 0.19 ± 0.07 |
| 161/08 (P11) | 28 Feb 2008 | Coronary | PEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT | D | I | 0.19 ± 0.1 |
| 155/08 (P12, M, 26) | 26 Feb 2008 | Intensive care | PEN, OXA, CEF, CLI, ERY, CHL, TET, RIF, GEN, CIP, SXT | C 1 | I | 0.48 ± 0.19 |
| 177/08 (P13, F, 59) | 26 Mar 2008 | Trauma | PEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXT | D | I | 0.90 ± 0.07 |
| 202/08 (P14, F, 14m) | 1 Apr 2008 | Paediatric unit | PEN, OXA, CEF, ERY, GEN, CIP, SXT | C 1 | I | NP |
| 207/08 (P15, M, 56) | 7 Apr 2008 | Neurology | PEN, OXA, CEF, CLI, ERY, RIF, GEN, CIP, SXT | ND | I | 0.44 ± 0.11 |
| 220/08 (P16, F, NB) | 26 Apr 2008 | Intensive care | PEN, OXA, ERY | M | I | NP |
| 283/08 (P17, F, NR) | 8 Jul 2008 | Dialysis | PEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT | E | I | 0.20 ± 0.06 |
| 285/08 (P18, M, NR) | 27 Jun 2008 | Surgery | PEN, OXA, CEF, ERY, CHL, TET, RIF, GEN, CIP, SXT | N | VII | 0.38 ± 0.15 |
| 286/08 (P19, M, 62) | 27 Jun 2008 | Intensive care | PEN, OXA, CEF, ERY, CHL, RIF, GEN, CIP, SXT | E | I | 0.24 ± 0.09 |
a : clinically significant isolates (for patient P4 the clinically significant isolate could not be assigned on the basis of the genotype, since the two isolates recovered had different genetic profiles); b : for these patients, clinical significance could not be evaluate due to lack of sufficient data; c : biofilm values were determined using a microtitre-based method; CEF: cefoxitin (30 µg); CHL: chloramphenicol (30 µg); CIP: ciprofloxacin (5 µg); CLI: clindamycin (2 µg); ERY: erythromycin (15 µg); F: female; GEN: gentamicin (10 µg); M: male; NB: newborn; ND: not-done; NP: non-producer; NR: not reported; OXA: oxacillin (1 µg); PEN: penicillin (10 U); RIF: rifampicin (5 µg); SXT: sulphamethoxazole-trimethoprim (1.25 µg/23.75 µg); TEI: teicoplanin (minimal inhibitory concentration ‰¥ 64 µg/mL); TET: tetracycline (30 µg). P4, P5, P6, P7, P10, P12, P17 were patients with significant bacteraemia.

A: biofilms of representative isolates of Staphylococcus haemolyticus (1: untreated; 2: proteinase K; 3: DNase; 4: sodium metaperiodate); B: microtitre based biofilm of representative isolates (1, 2: 33/08; 3, 4: 37/08; 5, 6: 69/08; 7, 8: ica -dependent biofilm producer Staphylococcus epidermidis 70D); even numbers: proteinase K treatment; odd numbers: untreated.